Pang Jian-Xin
Department of Pharmacology, The First Military Medical University, Guangzhou, Guangdong, 510515, PR China.
Ai Zheng. 2003 Aug;22(8):893-5.
Recently, a new immunotherapy against cancer based on a novel tumor-associated antigen of the human telomerase reverse transcriptase (hTERT) is being investigated. Antigen peptides derived from hTERT are expressed and presented with major histocompatibility complex (MHC) class I molecules in tumor cells, and elicit ex vivo cytotoxic T-lymphocyte (CTL) responses in healthy individuals and cancer patients. Data from both human and murine systems demonstrate that TERT-special CTL kill TERT-positive tumor cells of various histological origins in a MHC-restricted fashion. However, they do not lyze rarely normal cell types such as hematopoietic progenitor cells and activated T-lymphocytes in which telomerase has been detected. Phase I clinical trials targeting hTERT in advanced cancer patients further confirmed that there was little influence on autoimmunity. These results suggested that the possibility of broad spectrum immunotherapy or even immunoprevention therapy based on hTERT could be considered.
最近，一种基于人类端粒酶逆转录酶（hTERT）新的肿瘤相关抗原的新型癌症免疫疗法正在研究中。来源于hTERT的抗原肽在肿瘤细胞中表达，并与主要组织相容性复合体（MHC）I类分子呈递，在健康个体和癌症患者中引发体外细胞毒性T淋巴细胞（CTL）反应。来自人类和小鼠系统的数据表明，TERT特异性CTL以MHC限制的方式杀死各种组织学来源的TERT阳性肿瘤细胞。然而，它们很少裂解已检测到端粒酶的正常细胞类型，如造血祖细胞和活化的T淋巴细胞。针对晚期癌症患者的hTERT的I期临床试验进一步证实，对自身免疫几乎没有影响。这些结果表明，可以考虑基于hTERT的广谱免疫疗法甚至免疫预防疗法的可能性。
